Q4 2024 Management View Labcorp reported revenue of $3.3 billion for Q4 2024, an increase of 10% year-over-year, with Diagnostics and Biopharma segments each posting 10% growth. Chairman and CEO Adam ...

Adjusted operating profit grew across all segments, led by strong double-digit growth in US Pharmaceutical and Prescription Technology Solutions segment. In the Medical Surgical growth was lower than ...

Q3 2025 Management View Revenue for the quarter grew 18% to $95.3B, with adjusted operating profit increasing 16% to $1.5B. CEO Brian Tyler highlighted strong performance across the U.S.

Premature birth and low birth weight disrupt kidney development substantially, which leads to an increased risk of acute kidney injury, chronic kidney disease and hypertension. Broader awareness ...